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Overexpression of p53 protein is an independent prognostic indicator in
human endometrial carcinoma
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Summary The important role of the p53 gene in tumour progression and cellular response to DNA damage
has prompted investigation of the clinical significance of alterations to this gene. We examined both p53
overexpression and mutation of the gene in endometrial carcinoma in order to evaluate the prognostic
significance of these changes. Of 122 endometrial carcinomas, 33 (27%) showed overexpression of p53 in the
nucleus and 66 (54%) in the cytoplasm. Mutation in the p53 gene was found in 16 (13%) cases but showed no
significant association with patient survival. Nuclear p53 overexpression was associated with poor survival
(48% vs 80% alive in negative tumours 5 years post operatively, P<0.001). In contrast, cytoplasmic p53
overexpression was associated with better survival (85% vs 55%, P<0.001). When patients were separated into
prognostic subgroups according to established clinical markers, these associations remained significant within
most subgroups examined. In multivariate analysis adjusted for surgical stage, histological grade and type and
vascular invasion, both nuclear p53 overexpression [hazard ratio 4.9 (95% CI 1.3-17.6), P=0.016] and
cytoplasmic overexpression [0.25 (0.06-0.98), P=0.047] were independent prognostic factors. Immunohisto-
chemical assessment of p53 overexpression in the nucleus and cytoplasm could provide useful prognostic
information for the management of patients with endometrial cancer.
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Mutation of the p53 tumour-suppressor gene is the most
frequently observed genetic alteration in human cancer
(Levine et al., 1991). The p53 gene encodes a nuclear
phosphoprotein that normally initiates G1 cell cycle arrest
in response to DNA damage (Kuerbitz et al., 1992). This
extends the time available for DNA repair and prevents
genomic instability, hence the proposed role for p53 as a
'guardian of the genome' (Lane, 1992). In other situations,
perhaps related to cell type or extent of DNA damage, wild-
type p53 can also activate a form of programmed cell death
known as apoptosis (Lowe et al., 1994). Recent evidence
suggests that wild-type p53 is required for the apoptotic
response of some tumours to chemotherapy and radiotherapy
(Lowe et al., 1993, 1994). Because of its protective functions,
p53 status may therefore be an important prognostic
indicator for tumour response to adjuvant therapy and for
overall patient survival.
Wild-type p53 protein is present at low levels in normal
cells and is not usually visible using immunohistochemical
(IHC) techniques. Mutation of the p53 gene in tumours can
lead to stabilisation and accumulation of the protein so that
it becomes readily visible by IHC techniques (Levine et al.,
1991). It has been widely assumed that this represents
mutant, inactive forms of the protein that can no longer
carry out the protective functions of growth arrest and/or
apoptosis in response to DNA damage. This may account for
the association between nuclear p53 overexpression and
worse prognosis observed in several previous studies on
endometrial cancer (Inoue et al., 1994; Ito et al., 1994;
Nielsen and Nyholm, 1994; Reinartz et al., 1994). The
concordance between mutation and overexpression is not
absolute however and the presence of a mutation cannot
always be inferred from a positive IHC reaction and vice
versa (Wynford-Thomas, 1992).
In this study we examined the prognostic significance of
both p53 overexpression and gene mutation in 122
endometrial carcinomas from patients with a long follow-
up. Our results confirm that nuclear p53 overexpression is an
independent prognostic indicator of shortened survival. We
also report the novel observation of improved survival in
cases with cytoplasmic accumulation of p53 protein.
Materials and methods
Specimens
Paraffin-embedded tissue blocks from 122 patients operated
for primary endometrial carcinoma over the period 1979-87
were selected from the archives of King Edward Memorial
Hospital for Women. An emphasis was placed on high-grade
tumours and aggressive subtypes. Haematoxylin-and eosin-
stained sections were examined by a pathologist (KEW) to
enable selection of blocks with maximal tumour content. No
preoperative chemotherapy, hormonal therapy or irradiation
was conducted before surgical excision of tumours.
Histological classification was conducted according to
WHO (Poulsen et al., 1975) and staging by the International
Federation of Gynaecology and Obstetrics (FIGO) guidelines
(Creasman, 1989). The histological subtypes were endome-
trioid (94 cases), serous papillary (14), clear cell (four),
adenosquamous (three) and mucinous (seven). Other
clinicopathological parameters such as peritoneal cytology,
steroid receptor levels, myometrial invasion and surgical
management were also recorded in each patient report. The
median follow-up time was 60 months with a maximum of
165 months. At the end of the study period, 35 (29%)
patients had died as a result of spread of their primary
tumour.
Immunohistochemistry
Overexpression of p53 was detected using IHC as described
previously (Dix et al., 1994) with prior antigen retrieval by
microwave treatment (Gown, 1993). Two irradiations of
4 min each at 700 W in a 10 mmol 1-1 citrate buffer (pH 6.0)
were performed before blocking with 20% normal horse
serum. Polyclonal anti-p53 CM-1 antibody (Novocastra
Laboratories, UK), reported to recognise both wild-type
and mutant p53 epitopes in formalin-fixed, paraffin-
embedded tissue sections, was diluted at 1: 1000 in 20%
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normal horse serum/0.1% bovine serum albumin and
incubated with sections for 18 h at room temperature.
Positive controls were strongly staining colorectal tumour
specimens identified in a previous investigation (Dix et al.,
1994). These also served as negative controls by omission of
the primary antibody during otherwise identical incubations.
In addition, all cases were incubated with monoclonal
antibody DO-7 (Novocastra Laboratories) at a dilution of
1:20 but using otherwise identical IHC conditions. Slides
were evaluated independently for IHC staining by two
pathologists (KEW and SK) who had no prior knowledge
of clinicopathological features or patient outcome. Subcel-
lular p53 localisation (nuclear and/or cytoplasmic) and the
percentage of positive staining cells were recorded. Tumours
with greater than 5% of malignant cells staining positive by
IHC were considered to overexpress p53 protein.
Single-strand conformation polymorphism
DNA was extracted from paraffin-embedded tumour tissue as
described previously (Sparrow et al., 1995) and used as
template in polymerase chain reactions (PCRs) to amplify
exons 5-8 inclusive of the p53 gene (Dix et al., 1994). Single-
strand conformation polymorphism (SSCP) was then used to
screen for mutations within the PCR products. Two different
SSCP gel systems were used for the detection of mutations.
[32P]dCTP-radiolabelled PCR product was denatured in
formamide buffer (95% formamide, 10 mmol I1 EDTA,
0.05% bromophenol blue, 0.05% xylene cyanol) and the
single-stranded DNA separated on 50 cm length polyacryla-
mide gels (12% acrylamide/10% glycerol, 1800 V, 18 h run)
before visualisation of bands by autoradiography (Dix et al.,
1994). The second SSCP gel system used was separation of
non-isotopic PCR product on 8 cm length mini-gels (15%
acrylamide/5% glycerol, 150 V, 5 h run) and visualisation of
the single strands by silver staining. Gel staining consisted of
3 min in 10% ethanol, 3 min in 1% nitric acid, 10 min in 1%
silver nitrate, development in a sodium carbonate
(120 mg ml-') and formaldehyde (2.4 Ml ml-') solution then
fixation in 10% acetic acid for 5 min. All suspected mutations
were confirmed by separate PCR and using both radio-
isotopic and non-radioisotopic SSCP gel methods. In
preliminary experiments, we found the detection of muta-
tions using both systems to be identical for 41 different p53
mutations (R Soong, in preparation).
Statistical analysis
For statistical analysis, prognostic parameters were treated as
dichotomous variables as follows: FIGO stage (stage I/II vs
III/IV), histological grade (grade 1/2 vs 3), myometrial
invasion (less than one half vs greater than one half),
histological type (endometrioid vs non-endometrioid). Pa-
tients whose primary cause of death was not recurrent
endometrial cancer were censored from the study at the time
of death. The chi-square method was used to determine the
association between p53 alteration and other clinicopatholo-
gical parameters. Fisher's exact test was used when expected
frequencies fell below five in any cell. The Kaplan-Meier
method was used to construct survival curves for subgroups
of patients. Comparison of curves was done using the log-
rank test. Mutivariate analysis was performed using Cox's
proportional hazards method. All analyses were conducted
using the SPSS Software Package (Chicago, USA).
Results
Frequency ofp53 alterations in endometrial carcinoma
Sections of endometrial cancers were stained with the
polyclonal antibody CM-1 recognising wild-type and mutant
forms of p53 protein (Midgley et al., 1992). IHC positivity
was seen in both the nucleus (Figure la) and cytoplasm
(Figure lb) of tumour cells. Of the 122 cases examined,
nuclear staining was observed in 27%, cytoplasmic staining in
54% and concomitant staining in both in 4% (Table I).
Adjacent normal endometrial tissue was present in 53 cases.
Of these, 12 (23%) showed very light cytoplasmic staining
with CM-1.
Mutation of the p53 gene as detected by aberrantly
migrating bands in SSCP gels (Figure 2) was observed in
13% (16/122) of endometrial tumours. Six mutations were
found in exon 5, two in exon 6, eight in exon 7 and two in
exon 8. Two of the tumours contained two different
mutations. Of the tumours with exclusively nuclear staining,
9/28 (32%) contained a gene mutation, whereas 6/61 (10%)
of exclusively cytoplasmic staining tumours contained a
mutation.
Association ofp53 alterations with clinicopathologicalfeatures
Correlations between p53 alterations and the common
clinicopathological prognostic indicators for endometrial
cancer are summarised in Table I. Nuclear p53 overexpres-
sion associated significantly with the unfavourable prognostic
indicators of advanced surgical stage, high-grade morphol-
ogy, non-endometrioid histology, lymph node metastasis and
vascular invasion, and the absence of progesterone receptor.
In contrast, cytoplasmic p53 overexpression showed signifi-
cant correlation with the favourable prognostic indicators of
early surgical stage, low-grade morphology and absence of
lymph node and vascular invasion. p53 mutations were
associated with deep myometrial invasion, lymph node
metastasis and positive peritoneal cytology.
Association ofp53 alterations with patient survival
Kaplan-Meier survival analysis of various clinicopathologi-
cal features revealed that FIGO stage (P<0.001, Figure 3a),
Figure 1 Immunohistochemical detection of p53 protein in
endometrial carcinoma with CM-1 antibody. (a) Nuclear over-
expression. (b) Cytoplasmic overexpression. (Original magnifica-
tion x 200).
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histological grade (P=0.034), myometrial invasion
(P<0.001), peritoneal cytology (P<0.001) and lymph node
(P<0.001) and vascular invasion (P<0.001) were significant
predictors of survival. Overexpression of nuclear p53 was
associated with significantly worse prognosis (P<0.001;
Figure 3b). Five year survival rates were 48% for patients
with nuclear staining compared with 80% for those in which
there was no nuclear positivity. In contrast, cytoplasmic
staining correlated with improved survival (P<0.001; Figure
3c): 85% compared with 55% at 5 year follow-up. Mutation
of the p53 gene was associated with a trend towards worse
survival (Figure 3d), but this was not statistically significant
(P= 0.115).
Association of p53 alteration with survival was also
examined within the more favourable prognostic subgroups
of stage I/II, grade 1/2, endometrioid type and myometrial
invasion of less than one half (Table II). Overexpression of
nuclear p53 was associated with worse survival within all the
subgroups examined except surgical staging whereas cyto-
plasmic overexpression was associated with better survival in
all the subgroups. Interestingly, both p53 overexpression and
mutation were significant predictors of survival in the 106
patient subgroup treated post operatively with radiotherapy,
but not in the 41 patients treated by chemotherapy.
Multivariate analysis
Nuclear p53 overexpression was an independent prognostic
indicator of survival in multivariate analysis adjusted for
surgical staging, histological grade and type, vascular
invasion and the interactions between overexpression and
grade as well as grade and stage [hazard ratio 4.9 (95% CI
1.3-17.6), P=0.016]. Cytoplasmic overexpression was also
an independent prognostic indicator when adjusted for
surgical staging, histological grade and type, vascular
invasion and the interactions between overexpression and
stage as well as overexpression and grade [0.25 (0.06-0.98),
P=0.047]. The parameters of myometrial invasion, lymph
node metastasis and peritoneal cytology are automatically
accounted for in this analysis as they contribute to the
surgical staging.
Discussion
Recent advances in our understanding of the molecular basis
of tumour development and response to treatment have
opened up the possibility offinding novel and clinically useful
prognostic indicators. In particular, the central role played by
Table I Correlation between p53 alterations and clinicopathological features
Prognostic parameter
(no. ofpatients)
Total (122)
FIGO stage (122)
Stage I/II (91)
Stage III/IV (31)
Histological grade (122)
Grade 1/2 (75)
Grade 3 (47)
Histological type (122)
Endometrioid (94)
Non-endometrioid (28)
Myometrial invasion (111)
Invasion <0.5 (59)
Invasion >0.5 (52)
Peritoneal cytology (112)
Negative (96)
Positive (16)
Lymph node invasion (97)
Negative (78)
Positive (19)
Vascular invasion (122)
Negative (87)
Positive (35)
Progesterone receptor (67)
Negative (16)
Positive (51)
Oestrogen receptor (87)
Negative (13)
Positive (74)
Age (122)
<66
,66
Nuclear p53
overexpression
33 (27%)
19 (21%)
14 (45%)
(P = 0.009)
15 (20%)
18 (38%)
(P = 0.027)
18 (19%)
15 (54%)
(P<0.001)
13 (22%)
16 (31%)
(P = 0.296)
22 (23%)
7 (44%)
(P = 0.078)
14 (18%)
10 (53%)
(P = 0.006)
18 (22%)
14 (40%)
(P = 0.041)
8 (50%)
10 (20%)
(P = 0.025)
6 (46%)
18 (24%)
(P = 0.174)
17 (26%)
16 (29%)
(P = 0.727)
Cytoplasmic p53
overexpression
66 (54%)
56 (62%)
10 (32%)
(P = 0.005)
51 (68%)
15 (32%)
(P<0.001)
55 (58%)
11 (39%)
(P = 0.073)
35 (59%)
27 (52%)
(P = 0.433)
53 (55%)
7 (44%)
(P = 0.395)
52 (67%)
4 (21%)
(P<0.001)
53 (61%)
13 (37%)
(P = 0.017)
6 (38%)
29 (57%)
(P = 0.176)
6 (46%)
39 (53%)
(P = 0.663)
34 (52%)
32 (57%)
(P = 0.534)
p53 mutation
16 (13%)
9 (10%)
7 (23%)
(P = 0.119)
8 (11%)
8 (17%)
(P = 0.312)
9 (10%)
7 (25%)
(P = 0.052)
3 (5%)
11 (21%)
(P = 0.011)
10 (10%)
5 (31%)
(P = 0.039)
8 (10%)
6 (32%)
(P = 0.028)
9 (10%)
7 (20%)
(P = 0.233)
4 (25%)
5 (10%)
(P = 0.201)
2 (15%)
10 (13%)
(P>0.999)
10 (15%)
6 (11%)
(P = 0.469)p53 overexpression in endometrial carcinoma
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abnormalities of p53 function in neoplasia has stimulated
considerable interest in the use of alterations to this gene as
potential markers of tumour behaviour. Owing to its
technical simplicity most prognostic studies have used IHC
to detect p53 overexpression, the assumption being that this
represents mutant forms of the protein. In the present study
we detected nuclear p53 overexpression in 27% of
endometrial cancers using CM-1 antibody (Table I). A
survey of the literature revealed an identical frequency of
nuclear p53 overexpression (305/1150) in 13 previous IHC
studies of this cancer type using a variety of other anti-p53
antibodies (Bur et al., 1992; Kohler et al., 1992; Jiko et al.,
1993; Koshiyama et al., 1993; Ambros et al., 1994; Inoue et
al., 1994a,b; Ito et al., 1994; Khalifa et al., 1994; Lukes et al.,
1994; Nielsen and Nyholm, 1994; Reinartz et al., 1994;
Schneider et al., 1994).
We found nuclear p53 overexpression to be an indepen-
dent prognostic marker of worse survival in endometrial
cancer (Figure 3b). Although we have only presented data
obtained using CM-1 polyclonal antibody, similar results
were obtained with the DO-7 monoclonal antibody (not
shown). Our findings confirm previous reports of an
association between nuclear p53 overexpression and worse
prognosis in endometrial cancer (Inoue et al., 1994b; Ito et
al., 1994; Nielsen and Nyholm, 1994; Reinartz et al., 1994),
however only the present study and that of Ito et al. (1994)
found this to be an independent risk factor. Results from five
separate studies using a variety of different anti-p53
antibodies appear therefore to provide conclusive evidence
for an association between nuclear p53 overexpression and
worse prognosis in this cancer type.
The major and novel observation from our work is that
cytoplasmic p53 staining with CM-1 antibody is an
independent prognostic indicator of improved survival in
endometrial cancer (Figure 3c). With the exception of just
two cases reported to show cytoplasmic staining in this
cancer type (Inoue et al., 1994a), all previous studies have
found exclusively nuclear staining using the anti-p53
antibodies 1801, DO-7 or DO-1 antibodies. In agreement
with this we found only nuclear positivity when parallel
sections were incubated with DO-7 (results not shown),
suggesting the cytoplasmic staining we observed was due to
the use of CM-1 antibody. A number of other investigators
have shown cytoplasmic staining in a variety of cancer types
including breast (Moll et al., 1992; Domagala et al., 1993;
Stenmark-Askmalm et al., 1994), colorectal (Sun et al., 1992;
Bosari et al., 1994), glioblastomas (Ali et al., 1994),
undifferentiated neuroblastoma (Moll et al., 1995) and lung
(Iggo et al., 1990). In one of these studies, Western blotting
was used to confirm that CM-1 detected p53 in cytoplasmic-
staining neuroblastomas (Moll et al., 1995). The biological
significance of cytoplasmic p53 remains controversial
however and the possibility of cross-reaction between CM-1
polyclonal antibody and one or more cytoplasmic proteins
other than p53 cannot be excluded.
The few studies to date that have analysed cytoplasmic-
staining tumours for p53 mutations, including our own,
found normal allelotype in the large majority of cases (Moll
et al., 1992, 1995; Ali et al., 1994; Bosari et al., 1995).
Mutation of the nuclear localisation signals contained within
the carboxyl-terminal domain (codons 290-393) was not
found in cytoplasmic-staining breast tumours (Moll et al.,
1992) or undifferentiated neuroblastomas (Moll et al., 1995)
a
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Figure 2 PCR-SSCP detection of p53 gene mutation in
endometrial cancers. Lanes 2 (sample E5) and 4 (E8) demon-
strate the wild-type (WT) banding profile, while lanes 1 (E4), 3
(E7) and 5 (E12) contain additional, aberrantly migrating bands
(arrows), indicating the presence of a gene mutation (M) in these
specimens.
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Table II Kaplan-Meier survival analysis of p53 alterations within patient subgroups
Nuclear p53 Cytoplasmic p53 p53
Subgroup overexpression overexpression mutation
(no. ofpatients) (P) (P) (P)
Total (122) 0.001 0.001 0.115
Prognostic subgroups
FIGO stage I/II (91) 0.100 0.014 0.505
Grade 1/2 (75) <0.001 0.009 0.286
Endometrioid type (94) 0.043 0.003 0.876
Myo. Invasion <0.5 (59) 0.002 0.021 0.888
Treatment subgroups
Radiotherapy (106) 0.002 0.003 0.043
Chemotherapy (41) 0.209 0.160 0.236
and hence is unlikely to account for the accumulation of p53
in this compartment. Instead it has been proposed that p53 is
sequestered into the cytoplasm following binding to viral or
cellular proteins and may therefore represent an alternative
mechanism to mutation in causing functional inactivation of
this gene in tumour cells (Moll et al., 1992). Another study
suggests the intracellular distribution of p53 can be
modulated by the conformation of the protein (Zerrahn et
al., 1992). Adding to this are reports of cytoplasmic staining
in normal breast epithelial cells (Moll et al., 1992; Takahashi
and Suzuki, 1994), small hepatocytes (Zhao et al., 1994) and
normal endometrium (present study), suggesting that it may
also be a physiological phenomena.
In view of the uncertainty surrounding the nature of
cytoplasmic staining with CM-1, it would seem premature to
speculate on the basis of its association with improved
survival in endometrial cancer patients. Similar to our
findings, Moll et al. (1992) found a favourable prognosis
for cytoplasmic-staining inflammatory breast carcinomas
whereas the nuclear-staining tumours showed a worse
outcome. In contrast to these results, two large investiga-
tions of colorectal cancer found an association between
cytoplasmic CM-1 staining and worse prognosis (Sun et al.,
1992; Bosari et al., 1994). It is difficult to reconcile the
differences between these cancer types based on p53 mutation
status alone as all the studies to date including our own
indicate that cytoplasmic-staining tumours contain wild-type
p53 (Moll et al., 1992; Ali et al., 1994; Bosari et al., 1995).
The present study is the first to analyse both p53
overexpression and gene mutation in a large series of
endometrial cancers. Although the frequency of p53
mutation we observed was quite low (13%) in comparison
with most other major cancer types, survey of the literature
revealed an overall frequency of just 18% (54/298) for this
cancer type (Okamoto et al., 1991; Risinger et al., 1992;
Enomoto et al., 1993, 1995; Honda et al., 1993; Kohler et al.,
1993; Schneider et al., 1994; Kihana et al., 1995). Our results
show a trend towards worse prognosis for tumours with a
p53 gene mutation (Figure 3d), however this did not reach
significance (P=0.11). With the exception of a recent report
of poorer outcome for endometrial cancers with both p53
mutation and loss of heterozygosity (Kihana et al., 1995),
patient numbers in previous studies have been too small to
assess the prognostic significance of p53 mutations.
In conclusion, we found that nuclear and cytoplasmic p53
overexpression detected with CM-1 antibody were associated
with worse and improved prognosis respectively in endome-
trial cancer. These correlations were independent of the
established prognostic parameters of surgical stage, histolo-
gical grade and type and vascular invasion. The differential
staining was observed in a large proportion (73%) of
endometrial cancers, raising the possibility of obtaining
significant prognostic information from a single, routine
IHC reaction. The additional information obtained may help
to identify patients with early-stage and low-grade tumours
who have a high risk of recurrence but are not detected using
current clinical and pathological assessment procedures.
These patients present the greatest difficulty in terms of
planning the most appropriate treatment strategy. Over-
expression of p53 in the nucleus and cytoplasm detected with
the CM-1 antibody therefore has great potential as a novel
prognostic indicator in endometrial cancer and future studies
should aim to confirm our findings in larger retrospective and
prospective studies of early-stage/low-grade tumours.
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